{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/generalized-anxiety-disorder/prescribing-information/diazepam/","result":{"pageContext":{"chapter":{"id":"207b91a3-65a7-5bfa-a236-8e796e759e3e","slug":"diazepam","fullItemName":"Diazepam","depth":2,"htmlHeader":"<!-- begin field 377a7375-d859-4268-ac4c-cd0c934ac08f --><h2>Diazepam</h2><!-- end field 377a7375-d859-4268-ac4c-cd0c934ac08f -->","summary":"","htmlStringContent":"<!-- begin item b0add41e-7862-4e5d-960d-90a9b3e777ab --><!-- end item b0add41e-7862-4e5d-960d-90a9b3e777ab -->","topic":{"id":"a764014a-3ca0-5cd4-899a-93af1654f111","topicId":"135bad2d-5cd6-4df9-b7cf-450677581600","topicName":"Generalized anxiety disorder","slug":"generalized-anxiety-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"d7012fbb-d31d-52bd-8499-a790966332f6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ed3d6d57-ce79-58cd-9db0-91ce375231d0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"da5c6fdc-0857-531f-acff-dee7423b2434","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6d8405f1-6ec4-51b4-bc67-ce1dc419f266","slug":"changes","fullItemName":"Changes"},{"id":"dec78b2e-8a69-5c4e-9649-18c59fdff0ff","slug":"update","fullItemName":"Update"}]},{"id":"22e0cf56-e3b6-5744-9fc6-844673300989","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b1e50b04-250b-56d8-b08c-a5e9adc44ecb","slug":"goals","fullItemName":"Goals"},{"id":"62e69cfa-f1e2-54d6-bea8-71f618ecc0f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b044e4ad-382a-5b80-aa6f-0a91d1340216","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b3327928-a8a3-5312-a69d-3d1d69eca670","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a17705aa-783b-5363-8976-4095f0991e87","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"90f89dcc-cd30-59a4-a72e-1b755aec96f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4e9ebfa7-2592-5db9-aa36-cc7c2b32fb70","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"96d96d1d-9961-5dca-a6f4-3327704e9832","slug":"definition","fullItemName":"Definition"},{"id":"736e4407-30b1-5e9c-a715-ca54b10fb58a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9ca6a146-b065-5743-a95f-2c3ec5008efa","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f4bc4fe6-8936-515a-b07f-8c5d46c63495","slug":"complications","fullItemName":"Complications"},{"id":"71703d6d-00c1-5c15-b2b8-a2c1efc837fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8866064e-cc95-5d6d-aeb3-eda0b5463df2","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ed05a1cb-3048-5b62-a242-791415e2e034","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"55866755-f806-55a8-86b7-8e4e99072d8d","fullItemName":"Management","slug":"management","subChapters":[{"id":"93c33dd9-6fcf-5051-9acd-2fd56cad3d31","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"380e5777-c6f3-595b-ac6c-088be521e448","slug":"escitalopram-paroxetine-sertraline","fullItemName":"Escitalopram, paroxetine, and sertraline"},{"id":"e3d86ad6-7dbe-55e6-a0c6-d220d4b12b36","slug":"duloxetine-venlafaxine-modified-release","fullItemName":"Duloxetine and venlafaxine modified-release"},{"id":"96f243eb-7691-57e6-b968-6eeb41bc896d","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"207b91a3-65a7-5bfa-a236-8e796e759e3e","slug":"diazepam","fullItemName":"Diazepam"}]},{"id":"5c9792a8-5756-5d84-84c2-8301657b8478","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"795e451d-3583-5146-ab5d-137780924ebc","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c9dc003a-66b8-5907-95b0-90c4ce0ea1d5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5bcc68a1-3691-5684-8f30-113cd9b37910","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7fd23b16-785c-5716-bc47-74a34f4360f5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c7cfd852-0440-5a24-a57e-2d0dba08a1f2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4c65ec3e-2f85-5406-949d-d124e96e2e26","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d942b94-767d-5df9-82b9-f744d7714cd4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"9ddc5697-397c-5584-96e2-3e6bfde8da68","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 985d1c6e-e1a6-45d7-860c-c77a94c83214 --><h3>Contraindications and cautions of diazepam</h3><!-- end field 985d1c6e-e1a6-45d7-860c-c77a94c83214 -->","summary":"","htmlStringContent":"<!-- begin item 7504a27e-6058-45cf-9448-33e1db4b716b --><!-- begin field c5d318c5-e97e-4457-b3e6-f7a72deafe28 --><ul><li><strong>Do not prescribe diazepam to people </strong><strong>with:</strong><ul><li>Current or a history of alcohol or opioid use or misuse — alcohol and opioids can induce lethal sedation by potentiating the effects of diazepam.</li><li>Acute porphyria.</li><li>Myasthenia gravis — condition may be aggravated.</li><li>Sleep apnoea — condition may be aggravated.</li><li>Bronchitis or chronic obstructive pulmonary disease.</li><li>Severe hepatic insufficiency — elimination half-life may be prolonged.</li><li>Major depression.</li><li>Phobic or obsessional states, psychosis or schizophrenia, hyperkinesis — paradoxical reactions may occur.</li></ul></li><li><strong>Prescribe diazepam with caution to:</strong><ul><li>People with personality disorders.</li><li>The elderly, due to the increased risk of falls — the manufacturer advises halving the recommended doses.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field c5d318c5-e97e-4457-b3e6-f7a72deafe28 --><!-- end item 7504a27e-6058-45cf-9448-33e1db4b716b -->","subChapters":[]},{"id":"806a1963-6f55-5626-9fcd-f3f4806c139e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6dc0217b-1369-4b7c-ae6b-1f0daf623699 --><h3>What are the adverse effects associated with diazepam?</h3><!-- end field 6dc0217b-1369-4b7c-ae6b-1f0daf623699 -->","summary":"","htmlStringContent":"<!-- begin item 7a207fbd-f3c2-4a09-9b39-9b108de24935 --><!-- begin field ee423957-8f83-4cb9-9148-0f7184257eb5 --><ul><li><strong>The most common adverse effects of diazepam relate to its sedative effect </strong>and include drowsiness and decreased concentration. People who are taking benzodiazepines and drive should be given the following advice:<ul><li>It is an offence to drive after taking diazepam if you feel drowsy, dizzy, unable to concentrate, or make decisions.</li><li>It is an offence to drive if you have more than a specified amount of benzodiazepine in your body, whether your driving is impaired or not.<ul><li>Roadside saliva screening tests in the UK test for certain drugs that impair driving. If you have a positive roadside drug test for benzodiazepines, the police may ask you to provide a blood sample to measure the amount of benzodiazepine in your body.</li><li>If you are found to have more than the specified amount of benzodiazepine in your body, as long as your driving is not impaired, and you are taking your medicine on the advice of a doctor or pharmacist, you will be able to raise a statutory 'medical defence' and the police may not prosecute you.</li><li>It may be helpful to keep evidence that you are taking a benzodiazepine in accordance with medical advice with you while you are driving. Suitable evidence may include: your medication box with the pharmacy label on, or the other half of your prescription with the list of medicines prescribed by your doctor.</li></ul></li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Headache, vertigo, tremor, slurred speech, decreased libido, erectile dysfunction, gynaecomastia, and obstructive sleep apnoea syndrome.</li><li>Paradoxical effects such as talkativeness, excitement, irritability, aggression, antisocial behaviour, and suicidal ideation.</li><li>Tolerance and dependence — over time, users of benzodiazepines can develop tolerance and eventual dependence. For this reason, the National Institute for Health and Care Excellence recommends the use of benzodiazepines in the treatment of generalized anxiety disorder for a maximum of 2–4 weeks.</li><li>Withdrawal syndrome — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/benzodiazepine-z-drug-withdrawal/\">Benzodiazepine and z-drug withdrawal</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">Sweetman, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">National Collaborating Centre for Mental Health, 2011a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">DVLA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>] </p><!-- end field ee423957-8f83-4cb9-9148-0f7184257eb5 --><!-- end item 7a207fbd-f3c2-4a09-9b39-9b108de24935 -->","subChapters":[]},{"id":"c6179769-5912-5478-95f2-b4fd9b4d2512","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 3fc7164d-7ebb-423f-bbcb-da7dc55b7cdc --><h3>What are the key drug interactions with diazepam?</h3><!-- end field 3fc7164d-7ebb-423f-bbcb-da7dc55b7cdc -->","summary":"","htmlStringContent":"<!-- begin item 3532e695-739f-4a43-98ce-d4c9e79bc1bf --><!-- begin field f537158c-4466-4ee6-a8d6-6ac12a22e999 --><ul><li><p><strong>Drug interactions with diazepam include:</strong></p><ul><li>Alcohol and opioids — advise against concomitant use with diazepam. Alcohol and opioids can induce lethal sedation by potentiating the effects of diazepam.</li><li>Antihypertensives, vasodilators, and diuretics — be aware that concomitant use with diazepam may enhance the hypotensive effects of these drugs.</li><li>Drugs that inhibit cytochrome P450 enzyme (for example cimetidine, ciprofloxacin, azole antifungals, and oestrogens) — avoid concomitant use with diazepam. The metabolism of diazepam is mediated by cytochrome P450 isoenzymes; concomitant use with P450 inhibitors can result in increased serum levels of diazepam leading to increased effect.</li><li>Drugs that induce cytochrome P450 enzyme (for example St John's Wort and rifampicin) — be aware that cytochrome P450 inducers can accelerate hepatic elimination of diazepam and decrease its action. Dose adjustment of diazepam may be needed.</li><li>HIV protease inhibitors (ritonavir and indinavir) — concomitant use with diazepam is contraindicated. The interactions between HIV protease inhibitors and benzodiazepines are variable; however, the manufacturers of ritonavir and indinavir advise that concurrent use with diazepam is contraindicated.</li><li>Modafinil — monitor for adverse effects of diazepam as modafinil may increase the effects of diazepam. Dose adjustments of diazepam may be needed.</li><li>Phenytoin — monitor phenytoin concentrations as concomitant use with diazepam may increase or decrease serum concentrations of phenytoin.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field f537158c-4466-4ee6-a8d6-6ac12a22e999 --><!-- end item 3532e695-739f-4a43-98ce-d4c9e79bc1bf -->","subChapters":[]},{"id":"92292960-4da3-54ce-aece-c70ce0667a2b","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 02b4dec0-4059-4ac9-9735-85402b6b2db5 --><h3>What dose of diazepam should I prescribe?</h3><!-- end field 02b4dec0-4059-4ac9-9735-85402b6b2db5 -->","summary":"","htmlStringContent":"<!-- begin item 27b9e4c6-5a34-4d79-ad8d-b94355211182 --><!-- begin field ea3d2972-5a53-4d3e-8d23-4f5b5e9d6c18 --><ul><li>Prescribe the lowest possible dose for the shortest period of time and review the patient regularly. Treatment should not exceed 2–4 weeks.</li><li><strong>For anxiety, </strong>prescribe 2 mg three times a day.<ul><li>If needed, the dose can be increased to 15–30 mg daily in 3 divided doses (half the dose should be prescribed in elderly or debilitated people).</li></ul></li><li><strong>For insomnia associated with anxiety, </strong>prescribe 5–15 mg at bedtime.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field ea3d2972-5a53-4d3e-8d23-4f5b5e9d6c18 --><!-- end item 27b9e4c6-5a34-4d79-ad8d-b94355211182 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}